Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantern Pharma Inc. - Common Stock
(NQ:
LTRN
)
3.285
-0.135 (-3.95%)
Streaming Delayed Price
Updated: 12:42 PM EDT, Apr 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantern Pharma Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
May 06, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
May 02, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Recap: Lantern Pharma Q4 Earnings
March 18, 2024
Via
Benzinga
Lantern Pharma Earnings Preview
March 15, 2024
Via
Benzinga
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
May 01, 2024
Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.
Via
InvestorPlace
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
April 24, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
April 22, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
April 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 11, 2024
Via
Benzinga
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
April 10, 2024
EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(NYSE:MDT),(NASDAQ:NVDA),(NASDAQ:LTRN),(OTCQX:HWAIF),(TSX:AIDX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
March 31, 2024
No AI category went down in February, but 3 did in March - confirming my comment last week that
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
March 23, 2024
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
March 20, 2024
EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(OTCQX:HWAIF),(OTCQB:VRSSF),(NYSE:PATH),(NASDAQ:LTRN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
March 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 19, 2024
Via
Benzinga
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
March 18, 2024
LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
March 18, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Earnings Scheduled For March 18, 2024
March 18, 2024
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
March 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
March 11, 2024
Via
Benzinga
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
March 11, 2024
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
March 08, 2024
Via
Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
March 06, 2024
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 06, 2024
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
Via
Benzinga
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
March 05, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
March 04, 2024
From
Lantern Pharma Inc.
Via
Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Grand View Research says the global
Via
Talk Markets
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
February 20, 2024
Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
February 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.